Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Average Rating of “Hold” from Brokerages

Dynavax Technologies Corporation (NASDAQ:DVAX) has been assigned a consensus rating of “Hold” from the five ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $24.3333.

A number of research analysts have commented on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th.

Dynavax Technologies Price Performance

DVAX opened at $15.41 on Friday. The company has a market capitalization of $1.81 billion, a P/E ratio of -41.65 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The firm’s fifty day moving average price is $12.12 and its two-hundred day moving average price is $10.95. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $15.49.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The company had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. On average, analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current year.

Insider Activity

In other Dynavax Technologies news, COO David F. Novack sold 30,000 shares of the business’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total value of $464,700.00. Following the transaction, the chief operating officer directly owned 111,451 shares in the company, valued at $1,726,375.99. The trade was a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DVAX. Profund Advisors LLC increased its holdings in Dynavax Technologies by 2.7% during the 3rd quarter. Profund Advisors LLC now owns 38,380 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 995 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Dynavax Technologies by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock worth $2,694,000 after purchasing an additional 1,175 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares in the last quarter. Rafferty Asset Management LLC raised its holdings in shares of Dynavax Technologies by 0.9% in the third quarter. Rafferty Asset Management LLC now owns 164,206 shares of the biopharmaceutical company’s stock valued at $1,631,000 after buying an additional 1,516 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in Dynavax Technologies by 1.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 1,610 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.